Blog | HemaCare

Cancer CAR T Cell Therapy Adapted to Help Fight Threatening Fungal Infections

Sep 14, 2021 10:00:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, CAR-T, T Cells, Immunotherapy (Immunology)

0 Comments

Cryptococcus fungi infections can be fatal as the immune system struggles to fight off the invaders, but through immunotherapy called CAR T cell therapy, researchers are seeing positive results.

Cryptococcosis, a systemic fungal infection, is caused by the polysaccharide encapsulated yeasts Cryptococcus gatti and Cryptococcus neoformans. The disease can cause pneumonia and meningitis, as well as pathology in other tissues.

Read More

CAR T Cell Therapy Attacks Migrant Cells in the Immune System

Sep 7, 2021 10:10:00 AM / by Stacy Matthews Branch, DVM, PhD posted in CAR-T, T Cells

0 Comments

The FDA has currently approved CAR-T cell therapies that express CARs recognizing CD19. CD19 is expressed on top of the majority of B cells’ surface, allowing for specific B-cell malignancy therapies.

According to the American Cancer Society, there are approximately 5,690 new cases of and 1,580 deaths from acute lymphocytic anemia (ALL), most of which affect children. More than 18,000 people are diagnosed with diffuse large B-cell lymphoma (DLBCL) yearly, with the majority being people over the age of 60. B cells secrete antibodies that are antigen-specific. T cells work differently by directly attacking pathogenic or infected cells, and they also secrete inflammatory cytokines to induce additional immune cell involvement.

Read More

Genetically Engineered T-Cells May Lead to a New Immunotherapy for Type 1 Diabetes

Aug 31, 2021 10:15:00 AM / by Stacy Matthews Branch, DVM, PhD posted in CAR-T, T Cells

0 Comments

University of Arizona researchers created a new five-module chimeric antigen receptor T cell that has shown potential to fight against Type 1 diabetes.

Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction of pancreatic β cells by pathogenic, autoreactive T cells. Effective and safe immunotherapy approaches to treat T1D would enhance personalized medical approaches to mitigate the effects of pathogenic T-cell–mediated diseases such as T1D. A promising approach is the application of chimeric antigen receptor (CAR) T cells, given its known mechanism and current use to treat other diseases such as hematological cancers.

Read More

STAT5 Proteins May Play a Critical Role in Effective Anti-Tumor Immune Response

Jun 29, 2021 10:10:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, CAR-T

0 Comments

A study has shown that cancer patients’ white blood cells were genetically engineered to enable T-cells to identify and destroy the cancer cells.

Chimeric antigen receptor (CAR) T-cells are immune cells that have been genetically engineered to generate a T-cell receptor capable of targeting specific cancer cells. A patient’s own T cells are collected, modified, then infused back into the patient. Although very promising results and successes have been noted for the application of CAR-T cell therapy for blood cancers, it is not without significant challenges to overcome.

Read More

HemaCare Leukopaks Used to Evaluate CAR T Cell Therapy Potency

Nov 3, 2020 9:03:00 AM / by Nancy Andon, MSc posted in Leukopak, CAR-T, T Cells

0 Comments

A recent independent publication cites using HemaCare leukopaks for their evaluation of a CAR T cell therapy’s antitumor potency.

As the CAR T cell therapy field continues to grow, developers seek to refine techniques that will improve both the safety and efficacy of this promising cancer immunotherapy strategy. Scientists at Juno Therapeutics (Celgene) have been working to improve the potency of a CD19-targeted CAR T therapeutic currently in phase 1 and 2 clinical trials.

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts